Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01464034
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸The John Theurer Cancer Center @ Hackensack UMC, Hackensack, New Jersey, United States
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
- Conditions
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Registration Number
- NCT01410500
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT01402284
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT01372540
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT01351623
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 15
- Registration Number
- NCT01336920
- Locations
- 🇺🇸
Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 315
- Registration Number
- NCT01302392
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT01301807
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
- Conditions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT01279694
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT01246063
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.